Introduction
Pegylated liposomal doxorubicin (PLD) is a novel formulation with markedly delayed clearance, decreased volume of distribution, and accumulation of the drug in malignant tissues, which results in both higher therapeutic efficacy and reduced toxicity [1] . The accumulation and antitumor activity of liposomal doxorubicin in hepatocellular carcinoma (HCC) has already been shown in animals [2] . This phase II trial reports both the efficacy and toxicity of PLD in patients with locally advanced or metastatic HCC.
Patients and methods

Patients
Criteria for inclusion in this prospective, single-arm study were: age <75 years; measurable, histologically confirmed HCC unsuited for resection, transarterial embolization, or ethanol injection; Karnofsky index >60%; leucocyte count >3000/ul; thrombocyte count 80000/|il: normal left ventricular function; serum creatinine <1.5 mg/dl: serum bilirubin <3.0 mg/dl; prothrombin time < 1. 7 (INR); and aspartate aminotransferase < 5 times normal. Exclusion criteria were: liver cirrhosis stage Child-Pugh C; prior chemotherapy, chemoembolization. or radiotherapy; congestive heart failure > grade 2; myocardial infarction during the past three months, instable angina pectoris; brain metastasis; evidence of other malignant disease; pregnancy, or lactation. The study protocol was approved by the local ethics committee. All patients gave written informed consent prior to entry in the study. Treatment PLD (Caelyx*, Essex, Germany) was given at a dose of 30 mg/m 2 as intravenous infusion over one hour every three weeks until progression. After inclusion of five patients the dose was escalated to 40 mg/m 2 in absence of grade 3 and 4 toxicities. Antiemetics were not routinely given. The dose was reduced during the following cycles withholding PLD for any grade > 2 toxicity except of alopecia grade 3. In case of thrombocytopenia <60000/ul or leucocytopenia < 3000/uJ the dose was reduced by 50% and in case of thrombocytopenia <40000/ul or leucocytopenia < 1000/ul PLD was withheld.
Evaluation
Baseline examinations were: complete history and examination, electrocardiogram, echocardiography, complete blood count, serum a-fetoprotein, serum chemistry, T 2 weighted magnetic resonance imaging (MRI) of the liver using iron oxides as contrast medium, abdominal ultrasound, and chest X-ray. If MRI was not feasible, computed tomography was used. Response and toxicity were evaluated according to WHO criteria. Abdominal ultrasound and a-fetoprotein were performed prior to every cycle, and MRI. chest X-ray examinations, and echocardiography after cycles 3 and 6 or at the end of treatment.
Objective tumor response was the primary endpoint. Progressionfree survival, overall survival, and toxicity criteria were secondary endpoints. 
Statistics
The optimal two-stage design was used, in which the accrual would be terminated, if the response rate was < 3 of 17 patients. A response rate of > 3 of 17 patients would extend the accrual to 37 patients. This design has an a of 0.10 and p of 0.10.
Toxicity
Except for two hypersensitivity grade 4 reactions, therapy was well tolerated with only few grade 3 and 4 toxicities, but no cardiac toxicity. The most predominant grade 3 and 4 toxicities were increased liver enzymes in patients with preexisting grade 1 or 2 elevations (n -6) and hematologic toxicity (n = 5).
Discussion
Free doxorubicin has been shown to be superior to symptomatic treatment of HCC [3] , although recently published data of a metaanalysis revealed no efficacy of free doxorubicin for treatment of HCC [4] . Delivering doxorubicin by liposomes did not result in objective tumor response. Similar results were recently described for liposomal daunorubicin [5] . These results indicate, that liposomal entrapped anthracyclines are ineffective for the treatment of locally advanced or metastatic HCC. Liver function may worsen during chemotherapy in patients with liver cirrhosis. However, toxicity of PLD was low even in patients with underlying liver disease. In conclusion, PLD has no significant activity against advanced HCC. HCC is highly chemoresistant and will require new drugs to improve the outcome of therapy.
